VXRT vs. CRDL, XFOR, CRDF, CGEN, ADVM, CLLS, VCXB, KOD, LIFE, and VIGL
Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Cardiol Therapeutics (CRDL), X4 Pharmaceuticals (XFOR), Cardiff Oncology (CRDF), Compugen (CGEN), Adverum Biotechnologies (ADVM), Cellectis (CLLS), 10X Capital Venture Acquisition Corp. III (VCXB), Kodiak Sciences (KOD), aTyr Pharma (LIFE), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
Vaxart (NASDAQ:VXRT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
Cardiol Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -920.00%. Cardiol Therapeutics' return on equity of -98.90% beat Vaxart's return on equity.
18.1% of Vaxart shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 3.0% of Vaxart shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Vaxart has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Cardiol Therapeutics has lower revenue, but higher earnings than Vaxart. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cardiol Therapeutics had 4 more articles in the media than Vaxart. MarketBeat recorded 8 mentions for Cardiol Therapeutics and 4 mentions for Vaxart. Vaxart's average media sentiment score of 1.09 beat Cardiol Therapeutics' score of 0.83 indicating that Vaxart is being referred to more favorably in the media.
Vaxart received 292 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 65.47% of users gave Vaxart an outperform vote while only 54.84% of users gave Cardiol Therapeutics an outperform vote.
Vaxart currently has a consensus price target of $3.00, indicating a potential upside of 274.06%. Cardiol Therapeutics has a consensus price target of $7.00, indicating a potential upside of 195.36%. Given Vaxart's higher probable upside, research analysts plainly believe Vaxart is more favorable than Cardiol Therapeutics.
Summary
Cardiol Therapeutics beats Vaxart on 10 of the 17 factors compared between the two stocks.
Get Vaxart News Delivered to You Automatically
Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
